Blueshift Asset Management’s Axsome Therapeutics AXSM Stock Holding History

Blueshift Asset Management’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$304K	Buy	+1,796	New	+$310K	0.09%	340
2023 Q2	–	Sell	-3,763	Closed	-$232K	–	340
2023 Q1	$232K	Buy	+3,763	New	+$247K	0.1%	272
2022 Q4	–	Sell	-4,834	Closed	-$216K	–	357
2022 Q3	$216K	Buy	+4,834	New	+$242K	0.05%	492
2019 Q3	–	Sell	-31,544	Closed	-$812K	–	723
2019 Q2	$812K	Buy	+31,544	New	+$632K	0.11%	291

Other funds holding AXSM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Blueshift Asset Management's AXSM Position: Q1 2026 in Review

Blueshift Asset Management opened a new position in Axsome Therapeutics (AXSM) in Q1 2026: 1,796 shares worth $304K. The stake represents 0.09% of the portfolio and ranks #340 among its holdings. This is a return to the name: Blueshift Asset Management previously reported a position in AXSM as recently as Q1 2023.

Blueshift Asset Management first reported a position in AXSM in Q2 2019 and has held it in 4 quarters since. The position peaked at $812K in Q2 2019. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

Blueshift Asset Management held 1,796 shares of Axsome Therapeutics worth $304K as of Q1 2026.
Axsome Therapeutics was a new Blueshift Asset Management position in Q1 2026.
Axsome Therapeutics made up 0.09% of Blueshift Asset Management's portfolio in Q1 2026, its #340 holding.
Blueshift Asset Management first reported a position in Axsome Therapeutics in Q2 2019 and has held it in 4 quarters since.
Blueshift Asset Management's Axsome Therapeutics position peaked at $812K in Q2 2019.
409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Blueshift Asset Management's 13F filing for Q1 2026, filed 14 May 2026.